StartEDIN looks forward to welcoming you on Wednesday 25th of January at 6pm for our StartEDIN Lifesciences event.
At the event, the audience will hear from speakers in the Lifescience sector within Edinburgh. Our speakers will provide an insight into their business journey - obstacles they’ve faced, how they’ve overcome these challenges, how our city has supported them, their successes and what their business has become today.
Dr Clare Wareing is the founder of IpOncology, a consulting firm specialised in strategic clinical development. Previously, Clare has founded Nexus Oncology Ltd. From 1999 to 2012, Clare grew Nexus Oncology from a single office in Edinburgh to employing approximately 300 employees across 12 countries, placing it among the leading niche contract research organisations worldwide. Nexus was acquired by Ockham in 2012 and then by Chiltern in 2014. Claire has spent the 19 years conducting preclinical and clinical research in the oncology area. After starting her career researching the mechanisms of resistance to anticancer drugs, Dr. Wareing subsequently moved into clinical and strategic development of a variety of new cancer therapies. Her extensive industry experience in numerous types of cancer programs includes melanoma, breast cancer, colorectal cancer, CLL, and prostate cancer. Dr. Wareing has also been involved in the research supporting successful registration of agents such as CAMPATH®, Letrazole, Capecitabine, and Abiraterone and Ruxolitinib. Dr. Wareing has worked for large pharmaceutical companies, biotech companies and CROs and has gained an in-depth knowledge of all aspects of oncology drug development during her career.
Dr Phillip Cowley joined IOmet Pharma in January 2011 as Head of Chemistry. Prior to that he spent 15 years with Organon, Schering Plough and MSD where his roles included Medicinal Chemistry Section Head and leadership of projects at various stages from early discovery through clinical trials. Phill obtained his PhD in Chemistry in 1993 at UMIST, Manchester prior to moving to the University of Geneva as a Postdoctoral Fellow in the group of Professor Oppolzer. Phill is a Fellow of the Royal Society of Chemistry and a former Chairman of the Society for Medicines Research.
It is hoped that this event will encourage cross fertilisation across tech and life science enterprises and through the exchange of ideas, customs and methods help different groups understand motivators and how you can support one another within our city.
This event will offer an exciting opportunity for members to exchange knowledge and build relationships to ensure the Edinburgh region remains the best place for tech companies to start, grow and succeed.